An Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Health Care Team Outcomes of Selective Beta - 1 Blockers

Abstract

Among the cardio-selective beta-1-blockers are nebivolol, metoprolol, acebutolol, esmolol, betaxolol, bisoprolol, and atenolol. Heart failure, post-myocardial infarction, hypertension, chronic stable angina, and decreased left ventricular function following a recent myocardial infarction are among the conditions for which beta-1-selective blockers are FDA-approved. Preventing migraines, treating arrhythmias, reducing tremors, and treating the symptoms of anxiety disorders are among the non-FDA-approved use. Reduced morbidity and mortality following myocardial infarction is associated with their use. Beta-1 blocker therapy lowers the risk of congestive heart failure, coronary artery disease, and stroke. In order for providers to guide patient therapy regarding the treatment of indicated disorders as part of the interprofessional team, this activity provides information on the indications, mechanisms of action, administration techniques, significant adverse effects, contraindications, and monitoring of selective beta-1 antagonists. It also provides a foundation for optimal utilization based on current knowledge.